Beyond Today’s Implants: The Next Generation of Sustained Drug Delivery

1

Medication adherence is a significant challenge in glaucoma management, influenced by cost, complex regimens, and cognitive decline.
2

The FDA-approved iDose TR implant demonstrated sustained IOP reduction and safety through 36 months in clinical studies.
3

PolyActiva's PA5108 microimplant showed over 20% IOP reduction in phase 2a trials, with no adverse effects on corneal endothelium.
4

The BIM-IOL system aims to deliver bimatoprost for up to 3 years post-cataract surgery, showing a 34% mean IOP reduction in early studies.
5

Various investigational drug delivery platforms are being explored, including biodegradable implants and smart contact lenses.

1